Cancer Crosslinks 2023 – live stream

The live stream has now ended. There will be an article with highlights published on the website shortly.

Cancer Crosslinks 2023 takes place on 26 January 2023, starting 10:30 in Kaare Norum Auditorium at Oslo Cancer Cluster Innovation Park. The title of the programme is New dimensions to the hallmarks of cancer: How is the last decade of discoveries advancing our understanding of cancer biology and transforming precision medicine?

 

Watch the live stream here: 

 

View the programme here

A number of distinguished researchers will present at Cancer Crosslinks 2023

Meet the speakers of Cancer Crosslinks 2023

Join us for a day of educational talks and mingling with colleagues in the oncology community.

Cancer Crosslinks 2023 will take place on 26 January 2023 (starting at 10:30) in Kaare Norum Auditorium at Oslo Cancer Cluster Innovation Park.

International experts

The programme includes international experts sharing the latest advances in cancer precision medicine and immune-oncology.

The title of Cancer Crosslinks 2023 is New dimensions to the hallmarks of cancer: How is the last decade of discoveries advancing our understanding of cancer biology and transforming precision medicine. It is therefore appropriate that the day begins with a talk from the co-author of The Hallmarks of Cancer.

Douglas Hanahan

Douglas Hanahan

Douglas Hanahan, Distinguished Scholar of the Ludwig Institute for Cancer Research (Zurich/New York), Professor of Molecular Oncology, Swiss Institute for Experimental Cancer Research of the Swiss Federal Institute of Technology Lausanne, Switzerland will give a digital talk on The Hallmarks of Cancer: New Dimensions – Integrating Pre-Clinical and Clinical Cancer Trials of Mechanism-Targeted Therapies.

The three seminal publications are freely available via the following links:

  1. Hanahan D. & Weinberg R. A. (January 2000). “The Hallmarks of Cancer”. Cell. 100 (1): 57–70.
  2. Hanahan, D. & Weinberg, R. A. (March 2011). “Hallmarks of Cancer: The Next Generation”. Cell. 144 (5): 646–674.
  3. Hanahan, D. (Jan 2022) “Hallmarks of Cancer: New Dimensions”. Cancer Discov. 2022 Jan; 12 (1): 31–46.
Mariam Jamal-Hanjani

Mariam Jamal-Hanjani

Mariam Jamal-Hanjani, Group Leader, Cancer Metastasis Lab, CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute; Senior Clinical Lecturer and Honorary Consultant in Translational Lung Oncology, UCL Hospital, London, UK will give a talk on The natural history of non-small cell lung cancer evolution in TRACERx.

Nilofer Azad

Nilofer Azad

Nilofer Azad, Co-Director of Cancer Genetics and Epigenetics, Professor of Oncology, Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA will give a digital talk on Epigenetic (Combination) Therapy – exploiting complex biology to offer novel treatment options for patients with GI cancers.

Alpaslan (Aslan) Tasdogan

Alpaslan (Aslan) Tasdogan

Alpaslan (Aslan) Tasdogan Associate Professor, German Cancer Consortium (DKTK), Institute for Tumor Metabolism, Department of Dermatology, University Hospital Essen, Germany will give a talk on The metabolic regulation of cancer progression.

Thomas Nerreter

Thomas Nerreter

Thomas Nerreter, Junior Group Leader, Chair of Cellular Immunotherapy, Translational CAR-T Research Program, University Hospital and CCC Würzburg, Germany will give a talk on Cellular Therapy for solid and hematological tumors: novel targets and technologies.

Tom Erkers

Tom Erkers

Tom Erkers, Assistant Professor, Karolinska Institute, Stockholm, Sweden will give a talk on Data-driven hallmarks of acute myeloid leukemia: biological, prognostic & therapeutic implications.

Jakob Nikolas Kather

Jakob Nikolas Kather

Jakob Nikolas Kather, Professor of Clinical Artificial Intelligence, Else Kröner Fresenius Center for Digital Health, Technical University Dresden; Germany will give a talk on AI biomarkers in cancer: recent progress and the way to clinical implementation.

Norwegian moderators

Four Norwegian cancer researchers, representing the milieus at Oslo, Bergen and Trondheim, will guide the audience through the programme.

Katarina Puco

Katarina Puco

Katarina Puco, Senior Consultant Oncologist at Oslo University Hospital, Institute of Cancer research & Lovisenberg Diaconal Hospital, Oslo

Anna Pasetto

Anna Pasetto

Anna Pasetto, Associate Professor, Institute of Clinical Medicine, Division of Cancer Medicine, University of Oslo; Director of the Center for Advanced Cell Therapy (ACT) Cancer Clinic, Oslo University Hospital

May-Britt Tessem

May-Britt Tessem

May-Britt Tessem, Associate Professor/Research Scientist, Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU

Eli Sihn Samdal Steinskog

Eli Sihn Samdal Steinskog

Eli Sihn Samdal Steinskog, Consultant Oncologist, Department of Oncology, Haukeland University Hospital, Bergen, Norway

Mingling with colleagues

The educational programme is complemented by an afternoon networking session starting at 16:15 outside the auditorium. Don’t miss this opportunity to make new connections in the oncology community, revisit old acquaintances and engage in stimulating discussions with other health professionals.

One of the hallmarks of Cancer Crosslinks is the lively networking before, in-between and after the talks. Photo: Cameo UB

 

Register here

 

View and download the programme here

 

Visit the Cancer Crosslinks website here

 

Cancer Crosslinks 2023 is kindly sponsored by Bristol-Myers Squibb and Eli Lilly and Company.

 

                         

 

The gold label is awarded for excellent cluster management.

Gold Label awarded to Oslo Cancer Cluster

Oslo Cancer Cluster has received the Gold Label certificate from the European Cluster Excellence Initiative (ECEI) with an overall score of 94%.

The Gold Label certificate is granted by the European Cluster Excellence Initiative (ECEI) to cluster organisations that receive at least 80% on their cluster management excellence score. It is the highest recognition a European cluster organisation can achieve.

In October 2022, two independent cluster experts performed an assessment of all 31 quality indicators and awarded Oslo Cancer Cluster a score of 94%.

The indicators concern the quality of:

  • the structure of the cluster,
  • governance,
  • financing,
  • strategy,
  • services,
  • and recognition.

The assessment was performed through interviews with two members of staff. The interviews were also substantiated with relevant documentation.

This was the second time Oslo Cancer Cluster was assessed by the ECEI. The cluster received its first gold label with an overall score of 91% in December 2019.

The Gold Label certificate is valid for two years (until the end of 2024).

Armend Håti, CEO of ClexBio, received the Healthcare Prize from Trine Loe, Executive Vice President, DNB ASA, at DNB Nordic Healthcare Conference 2022.

Health companies gained investors’ attention

Strong Norwegian oncology presence at DNB Nordic Healthcare Conference 2022.

The DNB Nordic Healthcare Conference was back with in-person attendance last week, connecting some of the best Nordic health companies with eager investors at the DNB main office in Oslo.

“Health is key in Norway’s transition to a green economy. DNB shows great social responsibility by bringing together key players in business, investment, and health. It is encouraging to see the high-quality of the companies at this conference,” commented Ketil Widerberg, general manager at Oslo Cancer Cluster.

The conference included four different sessions with company presentations. A total of 14 members from Oslo Cancer Cluster were there, demonstrating the first-class cancer innovation emerging from Norwegian research environments.

The podcast Radium, produced by the investment fund Radforsk, also recorded an episode with perspectives on where the Nordic healthcare sectors.

 

Up-and-coming companies competed

Eleven health start-ups competed for the Health Prize of NOK 1 million during the Venture Session. Six members of Oslo Cancer Cluster were selected for this competition, and two were fast-tracked for the final. Here are snapshots from their pitches:

Bjørn Klem presented Adjutec Pharma, a company fighting against the global crisis of anti-microbial resistance.

Kerstin Jakobsson presented Kongsberg Beam Technology, a medtech start-up developing the next generation’s proton radiation therapy, by personalising the treatment for each patient.

Katja Vetvik presented Thelper, a Norwegian company that is developing targeted immunotherapies against cancer.

Peter W. Eide presented Oncosyne, a company that will provide game-changing functional diagnostic tools that give cancer patients significantly better and longer lives.

Torbjørn Furuseth presented DoMore Diagnostics, a company that is transforming cancer diagnostics with artificial intelligence.

Adam Robertson presented Hemispherian, a company developing a pipeline of first-in-class epigenetic therapeutics against aggressive cancers.

The companies ArxxTherapeutics, Bulbitech, Clexbio, Helseboka and Nadenod also pitched in this session. After a nerve-racking final, with heated discussions in the investor panel and a packed auditorium voting for their favorite start-up, Clexbio won the prestigious prize.

 

Oncology companies drew a crowd

There were two sessions with listed companies and one session with private companies, including 9 members from Oslo Cancer Cluster in total. The rooms filled up quickly, and the companies received many questions from curious investors. Here are some messages from their presentations.

Dan Schneider, CEO of Photocure, described how the company is improving the lives of bladder cancer patients with unique photodynamic technology for diagnosis and treatment. Visit the Photocure website to learn more.

Jan Alfheim, CEO of Oncoinvent, presented how the company uses alpha-emitting radiotherapeutics to kill all cancer cells in body cavities, including micro-metastatic disease. Visit the Oncoinvent website to learn more.

Martin Olin, CEO of BerGenBio, introduced how the company uses targeting AXL inhibitors to prevent the progression of cancer.

Visit the BerGenBio website to learn more.

 

Namir Hassan, CEO of Zelluna Immunotherapy, talked about how the company wants to save lives through innovative cancer-targeted cell therapies, using the unique TCR-NK technology.

Visit the Zelluna Immunotherapy website to learn more.

 

Per Walday, CEO of Exact Therapeutics, informed about how the company improves drug delivery with an ultrasound technology platform, using specifically designed microbubbles.

Visit the Exact Therapeutics website to learn more.

 

Mikael Engsig, CEO of Nykode Therapeutics, addressed how the company’s unique vaccine technology platform has the potential to be applicable to several disease areas.

Visit the Nykode Therapeutics website to learn more.

 

Carlos de Sousa, CEO of Ultimovacs, focused on the company’s next-generation universal cancer vaccine, that can educate the immune system to recognize telomerase, an enzyme that is expressed in 85% of all cancer types.

Visit the Ultimovacs website to learn more.

 

Erik Wiklund, CEO of Targovax, spoke about how the company wants to make PD1 checkpoint inhibitors work for all patients, with the company’s oncolytic therapy.

Visit the Targovax website to learn more.

 

The conference was organised by DNB with support from Oslo Cancer Cluster and Norway Health Tech. The event also collaborates with the following Norwegian clusters and networks in healthcare: The Life Science Cluster, Norwegian Smart Care Cluster, The Life Science Cluster, Norwegian Inflammation Network, Nansen Neuroscience Network and Aleap.